The role of antiplatelet therapy in patients with acute coronary syndromes is a moving target
with considerable novelty in the last few years. The pathophysiological basis of the treatment …

Aims: Several scoring systems, including the ABCD-GENE and HHD-GENE scores
incorporating clinical and genetic factors, have been developed to identify patients likely to …

Dual antiplatelet therapy (DAPT) has been paramount in preventing thrombosis following
percutaneous coronary intervention for nearly 3 decades. However, over the years, DAPT …

Introduction Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is a
cornerstone in the treatment of patients with acute coronary syndrome (ACS) undergoing …

Background CYP2C19 loss-of-function (LOF) alleles reduce the effectiveness of clopidogrel
and are associated with high rates of clinical events in patients undergoing percutaneous …

Objectives To investigate outcomes with selective, clopidogrel-based therapies versus
conventional treatment in patients undergoing percutaneous coronary intervention (PCI) …

For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary
syndrome (ACS) has been the only class I recommendation on DAPT in American and …

Introduction Dual antiplatelet therapy (DAPT) represents the cornerstone of secondary
prevention in patients presenting with acute coronary syndrome (ACS) and undergoing …

Background: Antiplatelet therapy deescalation has been suggested as an alternative to
standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding …

Dual antiplatelet therapy—the combination of aspirin and a P2Y12 inhibitor—remains the
standard antiplatelet regimen recommended to prevent ischemic complications immediately …